Ardelyx Reports $94.5 Million Revenue in Q1 2026, Driven by 38% Increase in Product Sales

Ardelyx, Inc. reported a total revenue of $94.5 million for the first quarter of 2026, marking a 27% increase from $74.1 million in the same period of 2025. The growth was primarily driven by a 38% rise in product sales, netting $93.4 million, with IBSRELA sales increasing by 58% to $70.1 million, while XPHOZAH sales remained stable at $23.3 million. The company’s net loss for the quarter was $37.6 million, a slight improvement from the $41.1 million loss reported in the prior year, resulting in a net loss per share of $0.15 compared to $0.17.

In terms of operational changes, Ardelyx has made significant strides in its product offerings and market presence. The company is actively pursuing the expansion of IBSRELA's eligible patient population to include chronic idiopathic constipation (CIC) patients, with a Phase 3 clinical trial (ACCEL) already underway. Additionally, the company has initiated pediatric clinical trials for IBSRELA, which could extend the product's patent life. However, the inclusion of XPHOZAH in the End-Stage Renal Disease Prospective Payment System (ESRD PPS) has raised concerns about its market potential, as Medicare Part D coverage for the drug was eliminated on January 1, 2025, negatively impacting revenue growth expectations.

Ardelyx's financial position has seen a decline in cash and cash equivalents, which decreased to $31.2 million from $68.0 million at the end of 2025. The company’s total liabilities increased to $355.9 million, up from $334.7 million, largely due to rising accounts payable and accrued expenses. The company’s employee headcount has also grown, reflecting its commitment to expanding its commercial and operational capabilities. Ardelyx continues to rely on third-party manufacturers for its products, which poses risks related to compliance and supply chain disruptions.

Looking ahead, Ardelyx remains focused on driving growth for IBSRELA and XPHOZAH while advancing its pipeline, including the development of RDX10531, a next-generation NHE3 inhibitor. The company has entered into a Sixth Amendment to its loan agreement, extending the maturity date of its loans and reducing interest rates, which is expected to provide additional financial flexibility. However, Ardelyx acknowledges the ongoing risks associated with regulatory changes, market competition, and the need for adequate coverage and reimbursement for its products, which could impact future revenue and operational success.